Godlee F. Goodbye PubMed, hello raw data. British Medical Journal 2011;342:d212
(doi: 10.1136/bmj.d212)
According to the Cochrane team, reviewers must have access to all unpublished data, not only from unpublished trials but also from those that have been published in peer reviewed journals. Reviewers must assess entire trial programmes, and if trial reports are incomplete, they should turn to reports from the drug regulators. Being this approach unsustainable across the whole of healthcare, the only real solution by the BMJ editor is that the raw data from trials must be made freely available. Journal editors have a key role to play in making this happen.
(doi: 10.1136/bmj.d212)
According to the Cochrane team, reviewers must have access to all unpublished data, not only from unpublished trials but also from those that have been published in peer reviewed journals. Reviewers must assess entire trial programmes, and if trial reports are incomplete, they should turn to reports from the drug regulators. Being this approach unsustainable across the whole of healthcare, the only real solution by the BMJ editor is that the raw data from trials must be made freely available. Journal editors have a key role to play in making this happen.
Comments